CA
CALC.US CalciMedica, Inc. Common Stock
- Market cap
- USD 8.34M
- P/E
- -
- P/B
- 2.07x
- ROE
- -137.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CALC.US undervalued?
Graham numberThe Graham number of CalciMedica, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CalciMedica, Inc. Common Stock fundamental analysis
No fundamental analysis for CalciMedica, Inc. Common Stock yet.
CalciMedica, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company…
Full company profileCalciMedica, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CalciMedica, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -175K | -303K | -395K | -519K | -52.0K | -58.0K | -58.0K | -46.0K | - |
| Operating Income | -28.6M | -37.5M | -29.8M | -35.9M | -14.2M | -38.1M | -24.2M | -23.1M | -19.2M |
| EBITDA | -28.2M | -36.7M | -29.4M | -35.4M | -7.64M | -34.2M | -13.6M | -28.1M | -4.44M |
| Net Income | -28.4M | -37.0M | -27.5M | -35.8M | -7.82M | -34.4M | -13.7M | -29.6M | -5.80M |
| EPS | -166 | -179 | -291 | -118 | -25 | -38 | -6.09 | -9.85 | -0.84 |
| Balance Sheet | |||||||||
| Total Assets | 17.8M | 40.7M | 102M | 69.1M | 3.35M | 12.2M | 19.8M | 13.6M | 14.3M |
| Total Liabilities | 5.79M | 12.3M | 7.01M | 4.07M | 12.6M | 4.03M | 5.38M | 20.2M | 10.1M |
| Shareholders' Equity | 12.0M | 28.4M | 94.8M | 65.0M | -9.23M | 8.16M | 14.4M | -6.64M | 4.23M |
| Cash & Short-term Investments | 12.8M | 36.0M | 95.0M | 63.7M | 1.33M | 11.2M | 18.7M | 13.0M | 13.8M |
| Total Debt | 78.8M | 131M | - | - | 5.36M | - | - | 9.70M | - |
| Cash Flow | |||||||||
| Operating Cash Flow | -28.2M | -31.2M | -32.1M | -31.5M | -11.8M | -25.7M | -21.1M | -21.2M | -17.8M |
| Capital Expenditure | 1.46M | 605K | 1.02M | 488K | 4.00K | 78.0K | 8.00K | 28.0K | 0.00 |
| Free Cash Flow | -29.7M | -31.8M | -33.1M | -32.0M | -11.8M | -25.8M | -21.2M | -21.2M | -17.8M |
| Ratios | |||||||||
| ROE | -236.1% | -130.4% | -29.0% | -55.1% | - | -421.2% | -95.1% | - | -137.2% |
| ROA | -159.3% | -91.1% | -27.0% | -51.8% | -233.6% | -282.0% | -69.2% | -217.5% | -40.6% |
| Debt to Equity | 6.56x | 4.62x | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
CalciMedica, Inc. Common Stock dividends
CalciMedica, Inc. Common Stock has not paid dividends in the last 8 fiscal years.
Last stock split: 1:5 on Aug 31, 2026.
Who owns CalciMedica, Inc. Common Stock
- Insiders 18.35%
- Institutions 57.36%
- Public & others 24.29%
- Shares outstanding 6.90M
- Free float 3.82M
Top funds holding CALC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Abante Quant Value FI | 28.3K | 0.08% | +105.85% | Aug 2026 |
| Fidelity Extended Market Index | 13.3K | 0.19% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 3.27K | 0.01% | 0.00% | Aug 2026 |
| Fidelity Series Total Market Index | 2.48K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 2.34K | 0.03% | 0.00% | Sep 2026 |
Top institutions holding CALC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Woodline Partners LP | 2.49M | 7.29% | 0.00% | Jun 2026 |
| Heights Capital Management Inc | 1.56M | 4.56% | 0.00% | Jun 2026 |
| StemPoint Capital LP | 1.24M | 3.65% | 0.00% | Jun 2026 |
| Squadron Capital Management LLC | 1.24M | 3.65% | 0.00% | Jun 2026 |
| Stonepine Capital Management Llc | 622K | 1.82% | 0.00% | Jun 2026 |
| L1 Global Manager Pty Ltd | 249K | 0.73% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 143K | 0.42% | 0.00% | Jun 2026 |
| CAMBRIDGE Invest RESEARCH ADVISORS, INC. | 120K | 0.35% | +100.00% | Jun 2026 |
| Geode Capital Management, LLC | 110K | 0.32% | -10.46% | Jun 2026 |
| Renaissance Technologies Corp | 97.3K | 0.29% | -24.03% | Jun 2026 |
| Vanguard Capital Management, LLC | 89.0K | 0.26% | -47.40% | Jun 2026 |
| 180 WEALTH ADVISORS, LLC | 83.4K | 0.24% | -34.07% | Jun 2026 |
| XTX Topco Ltd | 78.3K | 0.23% | 0.00% | Jun 2026 |
| HRT FINANCIAL LLC | 46.8K | 0.14% | +17.95% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 45.8K | 0.13% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 44.0K | 0.13% | +43.14% | Jun 2026 |
| Rockefeller Capital Management L.P. | 20.0K | 0.06% | +300.00% | Jun 2026 |
| GSA Capital Partners LLP | 17.5K | 0.05% | -26.53% | Jun 2026 |
| State Street Corp | 17.1K | 0.05% | 0.00% | Jun 2026 |
| TritonPoint Partners, LLC | 15.1K | 0.04% | 0.00% | Jun 2026 |
CalciMedica, Inc. Common Stock company profile
- Company name
- CalciMedica, Inc. Common Stock
- Ticker
- CALC.US
- Exchange
- USA Stocks
- Listed since
- Sep 25, 2020
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- 505 Coast Boulevard South, La Jolla, CA, United States, 92037
- Phone
- 858 952 5500
- Website
- calcimedica.com
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. Its lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. The company also develops Auxora for the treatment of ulcerative colitis, traumatic brain injury, and allergic asthma; and oral CRAC channel inhibitors for use in chronic inflammatory and immunologic disease. The company is based in La Jolla, California.
CalciMedica, Inc. Common Stock management
9- Dr. A. Rachel Leheny Ph.D.CEO & Director · born 1963
- Mr. Eric W. RobertsChief Business Officer & Vice Chairman of the Board · born 1964
- Dr. Sudarshan Hebbar M.D.Chief Medical Officer · born 1966
- Mr. Michael J. Dunn B.A., M.B.A.President & COO · born 1956
- Dr. Anjana Rao Ph.D.Co-Founder and Scientific Advisor
- Dr. Patrick Hogan Ph.D.Co-Founder and Scientific Advisor
- Dr. Stefan Feske M.D.Co-Founder and Scientific Advisor
- Dr. Kenneth A. Stauderman Ph.D.Co-Founder & Chief Scientific Officer · born 1954
- Mr. John M. Dunn J.D.General Counsel · born 1952